Search

everythinglearnresearchcommunity

for

Search:↓

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user is using oral and topical minoxidil, finasteride, dutasteride, and considering adding rosemary and pumpkin saw palmetto to their regimen. They report significant hair growth, especially with dutasteride, and are considering increasing their dose and adding RU58841.

Microneedling with finasteride, minoxidil, DMSO, and black seed oil shows mixed hair regrowth results. There are concerns about DMSO's safety and effectiveness.

A new serum claims to enhance hair regrowth by amplifying oxygen delivery, improving the effectiveness of treatments like exosomes and peptides. Users are skeptical, questioning its efficacy compared to established treatments like Minoxidil and Finasteride.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

The conversation discusses unconventional and satirical ideas for hair regrowth, including using umbilical cord cells, stem cells, and other humorous suggestions. It concludes with recommendations for more traditional methods like hair transplants or hair systems.

Cyclosporine A is discussed as a powerful hair growth stimulant, potentially more effective than minoxidil, but concerns about safety and side effects, including cancer risk, limit its use. The conversation highlights the need for further research and experimentation with topical application, despite its risks.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

A person noticed hair thinning, changed their diet, and added collagen and vitamins to see if it would improve hair growth before starting finasteride and considering a hair transplant. Commenters suggest the appearance of hair regrowth may be due to the way the hair is combed rather than actual growth.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

The conversation is about the potential benefits of Rapamycin for hair pigmentation and regeneration, based on effects observed in mice. The original poster is seeking personal experiences from others using Rapamycin for longevity.

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

Exosome stem cell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

A person experienced hair loss due to stress, hormonal changes, and possibly genetics, and tried treatments like minoxidil, finasteride, and dutasteride. They are now considering exosome therapy but are unsure about its effectiveness and which dermatologist to trust.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The conversation is about seeking updates on new hair loss treatments, specifically mentioning scube3 and GT20029, with one person mentioning HMI_115 as showing promising results.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation is about mesotherapy for hair regrowth, with suggestions to use microneedling combined with minoxidil, finasteride, or dutasteride instead. Mesotherapy is considered an expensive gimmick with no proven results.

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

The conversation discusses treatments for a receding hairline, specifically comparing microneedling with exosomes to injecting them. The user seeks recommendations for beginner-friendly resources, such as YouTube videos, to help start these treatments.

Exosome therapy for hair loss is questioned for its effectiveness and authenticity. Users express skepticism, citing manipulated photos and high costs.

Hypoxia may enhance hair growth by stimulating stem cells, but it could also risk fibrosis. Some users humorously discuss extreme methods like choking while using minoxidil, highlighting the need for new treatments.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.